CD274 and cancer: Examples include small molecule PD-L1 inhibitors, PD-L1-targeting PROTAC degraders, chemokine receptor antagonists, RORγt agonists, small molecule TGF-β inhibitors, small molecule STING agonists, etc. Although many of these are in clinical trials, no small molecule-based cancer immunotherapies have yet gained approval from the US Food and Drug Administration (FDA) [66].